Natera (NTRA) appoints independent director Thomas Lynch and expands board

Rhea-AI Filing Summary

Natera, Inc. expanded its Board of Directors from eleven to twelve members and appointed Thomas Lynch as a new director, effective June 2, 2026. He will serve as a Class I director with a term running until the 2028 annual stockholder meeting and has been deemed independent under Nasdaq standards. Lynch will join the Board’s Human Capital Committee and receive cash and equity compensation in line with Natera’s existing non-employee director program. His initial equity award will vest in three equal installments on June 26 of 2027, 2028, and 2029. The company also plans to enter into an indemnification agreement with him and notes there are no family relationships or related-party transactions requiring disclosure.

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Board size after change: 12 directors Director term end: 2028 annual meeting Equity vesting date 1: June 26, 2027 +3 more

6 metrics

Board size after change 12 directors Board size increased from eleven to twelve members effective June 2, 2026

Director term end 2028 annual meeting Initial term of Thomas Lynch as Class I director

Equity vesting date 1 June 26, 2027 First one-third of initial equity award vests

Equity vesting date 2 June 26, 2028 Second one-third of initial equity award vests

Equity vesting date 3 June 26, 2029 Final one-third of initial equity award vests

Effective appointment date June 2, 2026 Date Thomas Lynch joined Natera’s Board

Key Terms

Class I director, independent director, Human Capital Committee, equity compensation, +2 more

6 terms

Class I director financial

"Dr. Lynch will serve as a Class I director, with an initial term expiring at the 2028 annual meeting of stockholders."

A class I director is a member of a company’s board who belongs to one of several groups whose terms expire in a specified year under a staggered election system; each class is elected on a different cycle so only a portion of the board faces re-election each year. This matters to investors because it affects how quickly control of the board can change, the company’s continuity and oversight, and the ease of mounting or defending against takeover efforts—think of a team where only some players are replaced each season rather than the whole roster at once.

independent director regulatory

"The Board determined that Dr. Lynch qualifies as an independent director pursuant to the Securities Act of 1933, as amended, and the listing standards of The Nasdaq Stock Market."

An independent director is a member of a company's board of directors who is not involved in the company's day-to-day operations and has no significant relationships with the company that could influence their judgment. Their role is to provide unbiased oversight and ensure the company is managed in the best interests of all shareholders. This helps build trust and confidence among investors by promoting transparency and accountability.

Human Capital Committee financial

"The Board has appointed Dr. Lynch to the Human Capital Committee of the Board."

equity compensation financial

"Dr. Lynch will be entitled to receive cash and equity compensation consistent with that of the Company’s other non-employee directors."

Equity compensation is pay given to employees, executives or contractors in the form of company ownership—such as stock, stock options or restricted shares—rather than just cash. It matters to investors because it can align workers' incentives with shareholders (like paying someone in slices of the same pie they help grow), but it also increases the number of shares outstanding and company expenses, affecting ownership percentages and earnings per share.

Indemnification Agreement regulatory

"The Company also expects to enter into an Indemnification Agreement with Dr. Lynch, providing for indemnification and advancement of litigation and other expenses..."

An indemnification agreement is a contract in which one party promises to cover losses, costs, or legal claims that another party might face, acting like a tailored safety net or private insurance policy. For investors, it matters because such agreements shift potential financial risk away from a company or its officers and onto the indemnifier, which can affect a company’s future liabilities, cash flow and how risky the investment appears during deal-making or litigation.

Equity Incentive Plan financial

"Amended and Restated 2015 Equity Incentive Plan (incorporated by reference to Exhibit 10.1..."

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 2, 2026

Natera, Inc. 

(Exact name of registrant as specified in its charter)

Delaware

001-37478

01-0894487

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

13011 McCallen Pass
Building A Suite 100 

Austin, TX 78753

(Address of principal executive offices, including zip code)

(650) 980-9190

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

NTRA

Nasdaq Stock Market LLC (Nasdaq Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

The Board of Directors (the “Board”) of Natera, Inc., a Delaware corporation (the “Company”) (i) increased the size of the full Board from eleven to twelve members and (ii) appointed Thomas Lynch as a member of the Board, in each case effective as of June 2, 2026.

Dr. Lynch will serve as a Class I director, with an initial term expiring at the 2028 annual meeting of stockholders. There is no arrangement or understanding between Dr. Lynch and any other persons pursuant to which Dr. Lynch was elected as a director.

The Board determined that Dr. Lynch qualifies as an independent director pursuant to the Securities Act of 1933, as amended, and the listing standards of The Nasdaq Stock Market. The Board has appointed Dr. Lynch to the Human Capital Committee of the Board.

In connection with his appointment to the Board, Dr. Lynch will be entitled to receive cash and equity compensation consistent with that of the Company’s other non-employee directors. Such compensation is described in the Company’s Amended Compensation Program for Non-Employee Directors filed with the Securities and Exchange Commission (the “SEC”) on August 8, 2025 as Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025. The Company’s form Notice of Stock Unit Award and form Stock Unit Agreement were filed with the SEC on June 18, 2024 as Exhibit 10.1 to the Company’s Current Report on Form 8-K. The initial equity award granted to Dr. Lynch will vest as to one-third of the shares covered by such award on each of June 26, 2027, 2028, and 2029.

The Company also expects to enter into an Indemnification Agreement with Dr. Lynch, providing for indemnification and advancement of litigation and other expenses to Dr. Lynch to the fullest extent permitted by law for claims relating to his service to the Company or its subsidiaries. The Company’s form of indemnification agreement was filed with the SEC on March 16, 2017 as Exhibit 10.4 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016.

There are no family relationships between Dr. Lynch and any of the Company’s directors or executive officers, and Dr. Lynch does not have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Item 9.01. Financial Statements and Exhibits.

 (d) Exhibits.

Exhibit No.						Description
10.1						Natera, Inc. Amended Compensation Program for Non-Employee Directors (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 filed with the SEC on August 8, 2025).
10.2						Amended and Restated 2015 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on June 18, 2024).
10.3						Form of Indemnification Agreement (incorporated by reference to Exhibit 10.4 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016 filed with the SEC on March 16, 2017).
104						Cover Page Interactive Data File (formatted as inline XBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Natera, Inc.
			By:			/s/ Michael Brophy
						Michael Brophy
						Chief Financial Officer (Principal Financial and Accounting Officer)

Dated: June 5, 2026

FAQ

What board change did Natera (NTRA) announce in this 8-K?

Natera expanded its Board of Directors from eleven to twelve members and appointed Thomas Lynch as a new director, effective June 2, 2026. He will serve as a Class I director, with his initial term expiring at the 2028 annual meeting of stockholders.

Who is Thomas Lynch and what is his role at Natera (NTRA)?

Thomas Lynch has been appointed to Natera’s Board of Directors as a Class I director. He has been designated an independent director under the Securities Act and Nasdaq listing standards and will serve on the Board’s Human Capital Committee starting June 2, 2026.

How long will Thomas Lynch serve on Natera’s board under this appointment?

Thomas Lynch will serve as a Class I director with an initial term that expires at Natera’s 2028 annual meeting of stockholders. After that meeting, any continued service would depend on future stockholder elections and board decisions under the company’s governance structure.

What compensation will Thomas Lynch receive as a Natera (NTRA) director?

Thomas Lynch will receive cash and equity compensation consistent with Natera’s Amended Compensation Program for Non-Employee Directors. His initial equity award will vest in three equal parts on June 26 of 2027, 2028, and 2029, aligning with standard non-employee director practices.

What committee assignment did Natera give Thomas Lynch?

Natera’s Board appointed Thomas Lynch to its Human Capital Committee. This committee typically oversees matters related to people and compensation. His committee service begins with his board appointment effective June 2, 2026, alongside his broader responsibilities as a Class I director.

Does Thomas Lynch have related-party ties or family relationships at Natera?

Natera states there are no family relationships between Thomas Lynch and any of its directors or executive officers. The company also reports he has no direct or indirect material interest in any transaction that would require disclosure under Item 404(a) of Regulation S-K.

Will Natera provide indemnification protection to director Thomas Lynch?

Natera expects to enter into an indemnification agreement with Thomas Lynch, consistent with its standard form. This agreement provides indemnification and advancement of litigation and other expenses to the fullest extent permitted by law for claims related to his service to Natera or its subsidiaries.